Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2020-05-15 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于2019年度权益分派实施的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2019 annual equity distribution (dividend and stock bonus) by Anhui Anke Biological Engineering (Group) Co., Ltd. It details the dividend amount, stock transfer ratio, record date, ex-dividend date, and other procedural information. The document is relatively short (2723 characters) and focuses on the dividend distribution plan and its execution, not on presenting full financial statements or comprehensive annual results. It is not an annual report (10-K) or an earnings release (ER). It is a formal announcement of dividend amount and payment details, fitting the definition of a Notice of Dividend Amount (DIV).
2020-05-15 Chinese
关于第二期限制性股票激励计划部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the completion of a repurchase and cancellation of restricted shares under the company's second restricted stock incentive plan. It details the number of shares repurchased, the pricing basis, the reasons for repurchase, and the impact on the company's total share capital. The document includes board and shareholder meeting approvals, pricing adjustments, and confirmation of completion by the securities registration authority. This is a formal announcement about a share repurchase and cancellation event related to stock incentives, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion of financial results. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2020-04-30 Chinese
2019年度股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 Annual General Meeting (AGM) of Anhui Anke Bioengineering (Group) Co., Ltd. It details the legality and compliance of the AGM's convening, attendance, voting procedures, and resolutions passed. It does not contain the actual AGM materials or presentations but serves as a legal certification of the AGM process and results. The document length is 3517 characters, which is relatively short and consistent with a legal opinion or certification rather than the full AGM materials. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcement (DVA), as it confirms the voting results and legality of the AGM proceedings.
2020-04-29 Chinese
关于2019年度股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2019 Annual General Meeting (AGM) of 安徽安科生物工程（集团）股份有限公司. It details the voting results on various agenda items including the 2019 annual reports, profit distribution, appointment of auditors, remuneration plans, amendments to the company charter, and other corporate matters. The document includes specifics about the meeting date, voting methods, attendance, and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but rather the official results and decisions made at the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)' which covers official results from shareholder votes at any general meeting. The document length (7789 characters) and content confirm it is not merely a brief notice but a detailed voting results announcement. Therefore, the correct classification is DVA with high confidence.
2020-04-29 Chinese
2020年第一季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (only 349 characters) indicating that the company's full first quarter report for 2020 has been published and is available on the official disclosure website. It does not contain the actual financial data or substantive analysis itself, but rather directs investors to the full report. According to the 'MENU VS MEAL' rule, such a brief notice that a report has been published is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2020-04-28 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "安徽安科生物工程(集团)股份有限公司 2020 年第一季度报告全文" which translates to "Anhui Anke Biotechnology (Group) Co., Ltd. 2020 First Quarter Report Full Text." It contains detailed financial data for the first quarter of 2020, including revenue, net profit, cash flow, shareholder information, non-recurring gains and losses, business review, risk factors, and progress on fundraising projects. The document is comprehensive and includes actual financial statements and substantive financial analysis for a period shorter than a full fiscal year (quarterly). It is not a brief announcement or a certification letter but a full quarterly report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.